Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Oleksandra Stasyshyn
Observed names:
O Stasyshyn,
O. Stasyshyn,
O. V. Stasyshyn,
O.V. Stasyshyn,
Stasyshyn, Oleksandra,
Олександра Стасишин
show all 6
Institutions:
Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine,
National Academy of Medical Sciences of Ukraine
Observed institutions:
Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine,
National Academy of Medical Sciences of Ukraine
ORCID:
0000-0002-8366-5926
Observed ORCID:
0000-0002-8366-5926
OpenAlex ID:
A5010852837
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
2015
·
Barbara A. Konkle
, Oleksandra Stasyshyn
, et al.
·
Blood
·
287
PDF
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
2010
·
M. H. Wilcox
, G. R. Corey
, et al.
·
Journal of Antimicrobial Chemotherapy
·
228
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors
2023
·
Tadashi Matsushita
, Amy Shapiro
, et al.
·
New England Journal of Medicine
·
171
PDF
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
2023
·
Alok Srivastava
, Savita Rangarajan
, et al.
·
The Lancet Haematology
·
136
Randomized comparison of prophylaxis and on‐demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
2013
·
S. V. Antunes
, S. Tangada
, et al.
·
Haemophilia
·
131
PDF
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A
2016
·
Johnny Mahlangu
, Kazimierz Kuliczkowski
, et al.
·
Blood
·
99
Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study
2020
·
Robert Klamroth
, Jerzy Windyga
, et al.
·
Blood
·
94
PDF
Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A
2016
·
E. S. Mullins
, O. Stasyshyn
, et al.
·
Haemophilia
·
94
PDF
Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
2018
·
F. Peyvandi
, A. Mamaev
, et al.
·
Journal of Thrombosis and Haemostasis
·
78
PDF
Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A
2017
·
Sandrine Meunier
, Jayanthi Alamelu
, et al.
·
Thrombosis and Haemostasis
·
64
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B
2013
·
J. Windyga
, T. Lissitchkov
, et al.
·
Haemophilia
·
54
Safety, efficacy and pharmacokinetics of rVIII‐SingleChain in children with severe hemophilia A: results of a multicenter clinical trial
2017
·
O. Stasyshyn
, C. Djambas Khayat
, et al.
·
Journal of Thrombosis and Haemostasis
·
43
PDF
Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A
2020
·
Pratima Chowdary
, Eric S. Mullins
, et al.
·
Haemophilia
·
37
PDF
Prophylaxis with anti‐inhibitor coagulant complex improves health‐related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study
2014
·
O. Stasyshyn
, S. Antunes
, et al.
·
Haemophilia
·
30
Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open‐label, uncontrolled, multicentre, phase III study
2014
·
J. Windyga
, T. Lissitchkov
, et al.
·
Haemophilia
·
26
Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)
2021
·
Alok Srivastava
, Savita Rangarajan
, et al.
·
Blood
·
25
Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study
2024
·
Huyen Tran
, Sylvia von Mackensen
, et al.
·
Research and Practice in Thrombosis and Haemostasis
·
21
Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)
2016
·
Toshko J. Lissitchkov
, Evgeny Buevich
, et al.
·
Blood Coagulation & Fibrinolysis
·
18
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
2022
·
Steven W. Pipe
, Cédric Hermans
, et al.
·
Haemophilia
·
15
PDF
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
2021
·
Miguel Escobar
, Giancarlo Castaman
, et al.
·
Haemophilia
·
14
Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study
2024
·
Jerzy Windyga
, Shashikant Apte
, et al.
·
European Journal Of Haematology
·
13
PDF
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors
2021
·
Miguel Escobar
, James Luck
, et al.
·
Haemophilia
·
13
PDF
Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study
2023
·
Robert F. Sidonio
, Alexis A. Thompson
, et al.
·
Expert Review of Hematology
·
12
PDF
Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)
2020
·
Guenter Auerswald
, Claudia Djambas Khayat
, et al.
·
Journal of Blood Medicine
·
11
PDF
Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326)
2014
·
M. H. Solano Trujillo
, O. Stasyshyn
, et al.
·
Haemophilia
·
10
Show more works
View as search
Works count:
56
Citation count:
1,782
H-index:
18
I10-index:
25
Year
Topic
Type